Total Payments
$228,075
2024 Payments
$103,069
Companies
26
Transactions
663
Medicare Patients
17,287
Medicare Billing
$804,826
Payment Breakdown by Category
Other$145,096 (63.6%)
Travel$41,967 (18.4%)
Consulting$26,425 (11.6%)
Food & Beverage$14,494 (6.4%)
Education$92.96 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $142,515 | 110 | 62.5% |
| Travel and Lodging | $41,967 | 149 | 18.4% |
| Consulting Fee | $26,425 | 22 | 11.6% |
| Food and Beverage | $14,494 | 375 | 6.4% |
| Honoraria | $2,300 | 2 | 1.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $281.25 | 2 | 0.1% |
| Education | $92.96 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alnylam Pharmaceuticals Inc. | $95,412 | 226 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $44,835 | 81 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $24,833 | 59 | $0 (2024) |
| SCPHARMACEUTICALS INC. | $20,510 | 26 | $0 (2024) |
| Novo Nordisk Inc | $18,808 | 21 | $0 (2024) |
| Akcea Therapeutics, Inc. | $6,476 | 16 | $0 (2021) |
| Vifor Pharma, Inc. | $5,218 | 7 | $0 (2022) |
| Impulse Dynamics (USA) Inc. | $4,163 | 12 | $0 (2023) |
| Boston Scientific Corporation | $2,089 | 91 | $0 (2024) |
| Medtronic, Inc. | $1,994 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $103,069 | 244 | Alnylam Pharmaceuticals Inc. ($40,862) |
| 2023 | $78,515 | 206 | Alnylam Pharmaceuticals Inc. ($44,791) |
| 2022 | $22,765 | 119 | Alnylam Pharmaceuticals Inc. ($9,704) |
| 2021 | $23,725 | 94 | AstraZeneca Pharmaceuticals LP ($8,581) |
All Payment Transactions
663 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Travel and Lodging | In-kind items and services | $448.96 | General |
| Category: Genetic Disease | ||||||
| 12/17/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Travel and Lodging | In-kind items and services | $267.35 | General |
| Category: Genetic Disease | ||||||
| 12/17/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $76.32 | General |
| Category: Genetic Disease | ||||||
| 12/11/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/10/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $124.63 | General |
| Category: Genetic Disease | ||||||
| 12/05/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $3,908.75 | General |
| 12/05/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $563.56 | General |
| 12/05/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $433.13 | General |
| 12/05/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $246.23 | General |
| 12/05/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $212.06 | General |
| 12/05/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $104.39 | General |
| 12/04/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $265.00 | General |
| 12/03/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,755.00 | General |
| Category: Genetic Disease | ||||||
| 12/03/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,755.00 | General |
| Category: Genetic Disease | ||||||
| 12/03/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,620.00 | General |
| Category: Genetic Disease | ||||||
| 12/03/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,620.00 | General |
| Category: Genetic Disease | ||||||
| 12/03/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Travel and Lodging | Cash or cash equivalent | $318.82 | General |
| Category: Genetic Disease | ||||||
| 12/03/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Travel and Lodging | Cash or cash equivalent | $238.42 | General |
| Category: Genetic Disease | ||||||
| 12/03/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Travel and Lodging | In-kind items and services | $225.08 | General |
| Category: Genetic Disease | ||||||
| 12/03/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Travel and Lodging | Cash or cash equivalent | $121.27 | General |
| Category: Genetic Disease | ||||||
| 12/03/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: Genetic Disease | ||||||
| 12/03/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | Cash or cash equivalent | $19.00 | General |
| Category: Genetic Disease | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,750.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,481.00 | General |
| Category: Cardiovascular | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 3,673 | 8,437 | $598,546 | $204,245 |
| 2022 | 13 | 4,335 | 6,171 | $660,790 | $216,255 |
| 2021 | 12 | 4,536 | 5,650 | $582,761 | $201,954 |
| 2020 | 12 | 4,743 | 6,150 | $544,923 | $182,372 |
Total Patients
17,287
Total Services
26,408
Medicare Billing
$804,826
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 1,159 | 1,428 | $152,796 | $65,583 | 42.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 668 | 847 | $135,520 | $59,861 | 44.2% |
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 11 | 3,124 | $40,612 | $28,484 | 70.1% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 28 | 499 | $48,902 | $12,103 | 24.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 1,040 | 1,245 | $112,050 | $9,429 | 8.4% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 29 | 267 | $32,574 | $7,756 | 23.8% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 26 | 229 | $33,663 | $6,367 | 18.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 59 | 59 | $14,514 | $5,090 | 35.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 411 | 490 | $9,800 | $4,077 | 41.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 39 | 39 | $6,630 | $2,213 | 33.4% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 158 | 165 | $8,741 | $2,165 | 24.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 32 | 32 | $2,432 | $1,053 | 43.3% |
| 82565 | Blood creatinine level | Office | 2023 | 13 | 13 | $312.00 | $65.26 | 20.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 869 | 1,158 | $185,280 | $82,754 | 44.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 1,324 | 1,725 | $184,575 | $80,720 | 43.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 1,171 | 1,436 | $129,240 | $10,824 | 8.4% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 47 | 309 | $37,698 | $9,466 | 25.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 105 | 105 | $25,830 | $9,224 | 35.7% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2022 | 40 | 250 | $36,750 | $7,893 | 21.5% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2022 | 39 | 303 | $29,694 | $7,695 | 25.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 32 | 32 | $5,440 | $1,876 | 34.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 474 | 612 | $12,240 | $1,803 | 14.7% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2022 | 129 | 133 | $6,783 | $1,751 | 25.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 43 | 46 | $3,496 | $1,256 | 35.9% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 14 | 14 | $1,652 | $519.13 | 31.4% |
About Christopher Bell, ACNP
Christopher Bell, ACNP is a Acute Care healthcare provider based in Tupelo, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1225190382.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Christopher Bell, ACNP has received a total of $228,075 in payments from pharmaceutical and medical device companies, with $103,069 received in 2024. These payments were reported across 663 transactions from 26 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($142,515).
As a Medicare-enrolled provider, Bell has provided services to 17,287 Medicare beneficiaries, totaling 26,408 services with total Medicare billing of $804,826. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Acute Care
- Location Tupelo, MS
- Active Since 12/15/2006
- Last Updated 03/03/2016
- Taxonomy Code 363LA2100X
- Entity Type Individual
- NPI Number 1225190382
Products in Payments
- AMVUTTRA (Drug) $76,118
- WAINUA (Drug) $32,692
- FUROSCIX (Drug) $20,510
- CAMZYOS (Drug) $20,312
- ONPATTRO (Drug) $19,294
- FARXIGA (Drug) $10,693
- TEGSEDI (Drug) $5,563
- Veltassa (Drug) $5,205
- OPTIMIZER (Device) $2,601
- SYMPLICITY G3 (Device) $1,688
- Optimizer (Device) $1,562
- LEQVIO (Drug) $756.94
- LUX-Dx Insertable Cardiac Monitor (Device) $454.42
- WATCHMAN Access System (Device) $354.09
- Impella (Device) $350.29
- WATCHMAN (Device) $344.66
- VERQUVO (Drug) $271.45
- CARDIOMEMS (Device) $261.05
- JARDIANCE (Drug) $258.63
- FREESTYLE LIBRE PRO (Device) $250.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Acute Care Doctors in Tupelo
Megan Williams
Acute Care — Payments: $7,136
Acute Care $7,136
Starla Horton, Np, NP
Acute Care — Payments: $2,512
Acute Care $2,512
Robin Jackson
Acute Care — Payments: $2,295
Acute Care $2,295
Cynthia Smith, Acnp, ACNP
Acute Care — Payments: $1,204
Acute Care $1,204
Ginger Mcmillan-Buchanan, Acnp, ACNP
Acute Care — Payments: $750.14
Acute Care $750.14
Harminder Atwal, Acnp-Bc, ACNP-BC
Acute Care — Payments: $574.86
Acute Care $574.86